MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
11. März 2025 16:05 ET
|
MaxCyte, Inc.
ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and...
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
06. November 2024 16:05 ET
|
MaxCyte, Inc.
ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development,...
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
06. August 2024 16:05 ET
|
MaxCyte, Inc.
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
07. Mai 2024 16:05 ET
|
MaxCyte, Inc.
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 7, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused...
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
12. März 2024 16:05 ET
|
MaxCyte, Inc.
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
04. März 2024 16:05 ET
|
MaxCyte, Inc.
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD, March 4, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
08. Januar 2024 16:05 ET
|
MaxCyte, Inc.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD, January 8, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
08. November 2023 16:05 ET
|
MaxCyte, Inc.
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD, November 8, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte to Participate in Two Upcoming Investor Conferences
06. November 2023 16:05 ET
|
MaxCyte, Inc.
MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD, November 6, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling...
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
04. Oktober 2023 16:05 ET
|
MaxCyte, Inc.
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD, October 4, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...